Cooper Companies to acquire Sauflon, CooperVision partners with Turkish university

Article

The Cooper Companies, Inc. announced it has entered into definitive agreements to acquire Sauflon Pharmaceuticals for approximately $1.2 billion. Sauflon forecasts revenue of approximately $210 million for its fiscal year ending October 31, 2014, up approximately 22 percent year-over-year.

Pleasanton, CA-The Cooper Companies, Inc. announced it has entered into definitive agreements to acquire Sauflon Pharmaceuticals for approximately $1.2 billion. Sauflon forecasts revenue of approximately $210 million for its fiscal year ending October 31, 2014, up approximately 22 percent year-over-year.

The transaction is subject to regulatory approval and is anticipated to close prior to the company’s fiscal year end, October 31, 2014.

“We are extremely pleased to announce this acquisition which gives CooperVision the world's most comprehensive portfolio of daily disposable lenses,” says Robert S. Weiss, Cooper's president and chief executive officer. “CooperVision will now be able to offer a multi-tier daily strategy that includes a full suite of silicone hydrogel and hydrogel lenses, including options within all categories-spheres, torics, and multifocals. The daily segment is the fastest growing segment of the soft contact lens market and this transaction positions CooperVision as the premier company in this space.”

In related news, CooperVision recently partnered with Bogazici University’s College of Business in Istanbul, Turkey, to focus on developing its next generation of global leaders. As a component of the company’s Inspirational Leadership Program, a select group of senior leaders spent five days on campus earlier this year, immersing themselves in issues relating to entrepreneurship, governance, national culture and institutions, financial management and growing a high-caliber, emerging market workforce.

Bogazici University is ranked among the world’s top 200 institutions of higher education. Its dynamic faculty is internationally respected and globally connected, and highly able to share experiences and insights regarding the dynamic and sometimes volatile nature of multinational business challenges and opportunities.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.